We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
{\"0\":\"GKOS posted a narrower-than-expected Q2 loss and 29.7% revenue growth, beating the consensus estimate.\",\"1\":\"Revenues were driven by strong uptake of iDose TR and solid performance from Photrexa in corneal health.\",\"2\":\"The company raised 2025 revenue guidance but faces pressure from procedural bundling and coverage limits.\"}
Glaukos Corporation (GKOS - Free Report) reported second-quarter 2025 adjusted loss of 24 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 26 cents. The figure also improved from the year-ago quarter’s adjusted loss of 52 cents per share.
The GAAP loss per share was 34 cents compared with the prior-year quarter’s reported loss per share of $1.
Revenue Details
Glaukos registered revenues of $124.1 million in the second quarter, up 29.7% year over year on a reported basis and 29% at constant currency (cc). The figure also surpassed the Zacks Consensus Estimate by 8.1%.
Quarter in Detail
The company recorded net sales of $103.5 million for Glaucoma, up 36% year over year. Sales at Corneal Health were $20.6 million.
Glaukos Corporation Price, Consensus and EPS Surprise
Gross profit increased 32.9% year over year to $97.2 million. The adjusted gross margin was 83% compared with 82% in the year-ago period.
Selling, general and administrative expenses rose 25.9% year over year to $83.4 million. Research and development expenses totaled $36.5 million, up 6.1% year over year. Total operating expenses were $119.9 million, up 16.3% from the prior-year period.
The operating loss declined to $22.7 million from $29.9 million in the year-ago period. The adjusted operating loss was $16.6 million, narrower than the year-ago quarter’s reported loss of $23.7 million.
Financial Update
Glaukos exited the second quarter of 2025 with cash and cash equivalents and short-term investments of $278.6 million compared with $303.4 million at the end of first-quarter 2025.
2025 Guidance
The company raised its guidance for 2025 revenues. It now expects net sales in the range of $480-$486 million compared with previous guidance of $475-$485 million. The Zacks Consensus Estimate for the same is pegged at $480.2 million. The loss per share estimate is pinned at 81 cents, implying 56.5% improvement year over year.
Our Take
Glaukos exited the second quarter of 2025 with better-than-expected results, wherein earnings and revenues surpassed their respective consensus estimate. Management remains excited about the company’s continued top-line growth in the reported quarter.
Per management, GKOS’ top line in the second quarter was driven primarily by robust uptake of its iDose TR sustained-release therapy, which saw broad physician adoption following its U.S. commercial launch. The iStent franchise also contributed meaningfully despite pressure from policy-related procedure bundling. Corneal health sales, particularly Photrexa, were another highlight, aided by Medicare Drug Rebate Program benefits.
Glaukos made solid pipeline progress in the second quarter, highlighted by regulatory milestones for Epioxa, its novel, non-surgical keratoconus therapy, with FDA approval targeted by October 2025. The company is also advancing multiple programs across glaucoma, corneal, and retinal platforms, including pivotal trials for iStent infinite, iDose Tregs, and GLO-401. A strategic acquisition of Mobius Therapeutics further strengthens its glaucoma offering. Management emphasized disciplined investment and operational expansion, with cash balances increasing despite selective M&A and facility purchases. This broad, advancing pipeline reinforces long-term growth potential.
However, the company continues to face headwinds from restrictive Local Coverage Determinations, which are weighing on non-iDose stent volumes and contributing to a mid-single-digit decline in that part of the business. Cataract surgery trends and procedural bundling also pose short-term revenue mix challenges.
Shares of GKOS lost 2.2% during after-market trading following the second-quarter results. The company’s shares have lost 37.2% in the year-to-date period compared with the industry’s decline of 7.5%. The broader S&P 500 Index has increased 7.9% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank and Other Stocks to Consider
Currently, Glaukos carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
Key Takeaways
Glaukos Corporation (GKOS - Free Report) reported second-quarter 2025 adjusted loss of 24 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 26 cents. The figure also improved from the year-ago quarter’s adjusted loss of 52 cents per share.
The GAAP loss per share was 34 cents compared with the prior-year quarter’s reported loss per share of $1.
Revenue Details
Glaukos registered revenues of $124.1 million in the second quarter, up 29.7% year over year on a reported basis and 29% at constant currency (cc). The figure also surpassed the Zacks Consensus Estimate by 8.1%.
Quarter in Detail
The company recorded net sales of $103.5 million for Glaucoma, up 36% year over year. Sales at Corneal Health were $20.6 million.
Glaukos Corporation Price, Consensus and EPS Surprise
Glaukos Corporation price-consensus-eps-surprise-chart | Glaukos Corporation Quote
Margin Analysis
Gross profit increased 32.9% year over year to $97.2 million. The adjusted gross margin was 83% compared with 82% in the year-ago period.
Selling, general and administrative expenses rose 25.9% year over year to $83.4 million. Research and development expenses totaled $36.5 million, up 6.1% year over year. Total operating expenses were $119.9 million, up 16.3% from the prior-year period.
The operating loss declined to $22.7 million from $29.9 million in the year-ago period. The adjusted operating loss was $16.6 million, narrower than the year-ago quarter’s reported loss of $23.7 million.
Financial Update
Glaukos exited the second quarter of 2025 with cash and cash equivalents and short-term investments of $278.6 million compared with $303.4 million at the end of first-quarter 2025.
2025 Guidance
The company raised its guidance for 2025 revenues. It now expects net sales in the range of $480-$486 million compared with previous guidance of $475-$485 million. The Zacks Consensus Estimate for the same is pegged at $480.2 million. The loss per share estimate is pinned at 81 cents, implying 56.5% improvement year over year.
Our Take
Glaukos exited the second quarter of 2025 with better-than-expected results, wherein earnings and revenues surpassed their respective consensus estimate. Management remains excited about the company’s continued top-line growth in the reported quarter.
Per management, GKOS’ top line in the second quarter was driven primarily by robust uptake of its iDose TR sustained-release therapy, which saw broad physician adoption following its U.S. commercial launch. The iStent franchise also contributed meaningfully despite pressure from policy-related procedure bundling. Corneal health sales, particularly Photrexa, were another highlight, aided by Medicare Drug Rebate Program benefits.
Glaukos made solid pipeline progress in the second quarter, highlighted by regulatory milestones for Epioxa, its novel, non-surgical keratoconus therapy, with FDA approval targeted by October 2025. The company is also advancing multiple programs across glaucoma, corneal, and retinal platforms, including pivotal trials for iStent infinite, iDose Tregs, and GLO-401. A strategic acquisition of Mobius Therapeutics further strengthens its glaucoma offering. Management emphasized disciplined investment and operational expansion, with cash balances increasing despite selective M&A and facility purchases. This broad, advancing pipeline reinforces long-term growth potential.
However, the company continues to face headwinds from restrictive Local Coverage Determinations, which are weighing on non-iDose stent volumes and contributing to a mid-single-digit decline in that part of the business. Cataract surgery trends and procedural bundling also pose short-term revenue mix challenges.
Shares of GKOS lost 2.2% during after-market trading following the second-quarter results. The company’s shares have lost 37.2% in the year-to-date period compared with the industry’s decline of 7.5%. The broader S&P 500 Index has increased 7.9% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank and Other Stocks to Consider
Currently, Glaukos carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.